Skip to Main Content

Chester Mathis, PhD

Professor, Radiology


BS (Chemistry), 1972.
PhD (Chemistry), 1979.
Post-doc, 1979-1981.


Headshot of Chester Mathis, PhD

Dr. Mathis has a long standing interest in applying synthetic radiochemistry techniques to develop PET radiopharmaceuticals to study brain function in vivo. Over the past 25 years, he has focused primarily on the development of radiotracers to image the serotonin and dopamine neuroreceptor systems, as well as agents to evaluate other aspects of normal and abnormal function in the central nervous system using PET imaging techniques.

Approximately 10 years ago, Dr. Mathis joined efforts with Dr. William E. Klunk of the Department of Psychiatry at the University of Pittsburgh to devise a PET radiotracer capable of imaging amyloid. This work led to the development of a new class of highly successful radiopharmaceutical agents, among which is Pittsburgh Compound-B, to non-invasively assess amyloid load in the living human brain using PET imaging methodology.

As the Director of the University of Pittsburgh PET Facility, Dr. Mathis works closely with more than 25 University of Pittsburgh investigators from 8 departments on more than 70 PET research imaging protocols in animals and human subjects. These projects include neuroscience, diabetes, and oncology research studies using more than 40 different PET radiotracers to image a variety of biological processes in animals and human subjects.

Journal Articles

Wiley CA, BJ Lopresti, JT Becker, F Boada, OL Lopez, J Mellors, CC Meltzer, SR Wisniewski and CA Mathis. Positron emission tomography imaging of peripheral benzodiazepine receptor binding in human immunodeficiency virus-infected subjects with and without cognitive impairment. J Neurovirology 12:262-271, 2006.
Bertoldo A, JC Price, C Mathis, NS Mason, DP Holt, C Kelley, C Cobelli and DE Kelley. Quantitative assessment of glucose transport in human skeletal muscle: Dynamic PET imaging of [O-methyl-11C]3-O-methyl-D-glucose. J Clinical Endocrinology and Metabolism 90:1752-175, 2005.
Eiseman JL, C Brown-Proctor, PE Kinahan, JM Collins, LW Anderson, E Joseph, DR Hamburger, SS Pan, CA Mathis, MJ Egorin and RW Klecker. Distribution of 1-(2-Deoxy-2-fluoro-{ß}-D-arabinofuranosyl) uracil in mice nearing colorectal cancer xenografts: Rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase. Clin Cancer Res 10:6669-6676, 2004.
Klunk WE, H Engler, A Nordberg, Y Wang, G Blomqvist, DP Holt, M Bergstrom, I Savitcheva, G-F Huang, S Estrada, B Ausen, ML Debnath, J Barletta, JC Price, J Sandell, BJ Lopresti, A Wall, P Koivisto, G Antoni and CA Mathis. Imaging brain amyloid in Alzheimer’s disease using the novel PET tracer PIB. Annals of Neurology 55:306-319, 2004.
Mathis CA, Y Wang, DP Holt, G-F Huang, ML Debnath and WE Klunk. Synthesis and evaluation of 11C-labeled 6-substituted 2-aryl benzothiazoles as amyloid imaging agents. J Med Chem 46:2740-2755, 2003.